Bristol-Myers Squibb has reported mixed results from a trial of its two checkpoint inhibitors – Opdivo and Yervoy – in metastatic renal cell carcinoma (RCC), a form of kidney cancer. The combination ...
If you’re looking for certainty in immuno-oncology, Bristol-Myers Squibb’s latest trial data won’t help. The drugmaker reported mixed results from a test of its Opdivo-plus-Yervoy combination in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback